Ara
Toplam kayıt 6, listelenen: 1-6
Role of 68-Ga-PSMA-PET/CT in pelvic radiotherapy field definitions for lymph node coverage in prostate cancer patients
(2020)
Purpose: To evaluate the distribution of metastatic lymph nodes (LN) detected on Ga-68-PSMA-positron emission tomography/computed tomography (PET/CT) in treatment-naive prostate cancer (PC) patients and to analyze the LN ...
The effect of androgen deprivation therapy on Ga-68-PSMA tracer uptake in non-metastatic prostate cancer patients
(2020)
Purpose To evaluate the effect of neoadjuvant androgen deprivation treatment (ADT) on prostate-specific membrane antigen (PSMA) tracer uptake demonstrated in Ga-68-PSMA-positron emission tomography (PET/CT) in non-metastatic ...
The role of T2-weighted images in assessing the grade of extraprostatic extension of the prostate carcinoma
(2020)
Purpose Extraprostatic extension (EPE) is an unfavorable prognostic factor and the grade of EPE is also shown to be correlated with the prognosis of prostate cancer. The current study assessed the value of prostate magnetic ...
Retrospective correlation of (68)ga-psma uptake with clinical parameters in prostate cancer patients undergoing definitive radiotherapy
(2020)
Objective The aim of the study is to investigate the correlation between the intensity of prostate-specific membrane antigen (PSMA) uptake in primary tumor and clinico-pathological characteristics of non-metastatic prostate ...
Incidental testicular doses during volumetric-modulated arc radiotherapy in prostate cancer patients
(2020)
Purpose To compare the incidental testicular doses during volumetric-modulated arc therapy (VMAT) in patients receiving prostate-only and pelvic lymphatic irradiation. Materials and methods Testicular doses in 40 intermediate- ...
Stereotactic radiotherapy to oligoprogressive lesions detected with Ga-68-PSMA-PET/CT in castration-resistant prostate cancer patients
(2021)
Purpose We assessed the outcomes of stereotactic body radiotherapy (SBRT) to treat oligoprogressive castration-resistant prostate cancer (CRPC) patients with <= 5 lesions using gallium prostate-specific membrane antigen-positron ...